Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Simris Group

Simris Group AB (“Simris” or the “Company”) has entered into a Memorandum of Understanding (“MoU”) with Immunrise Biocontrol France SAS (“Immunrise”) regarding a potential divestment of the Company’s assets related to microalgae production in Hammenhög, Sweden.

The MoU concerns all assets associated with Simris’ production facility for microalgae in Hammenhög. The parties have agreed on an indicative valuation principle whereby the purchase price is expected to be in line with the book value of the assets, subject to satisfactory completion of legal, technical and operational due diligence, as well as the negotiation and execution of a definitive asset purchase agreement.

Under the MoU, Immunrise intends to conduct due diligence with the objective of submitting a firm and binding offer no later than 1 March 2026. Subject to the outcome of the process, the parties aim to enter into a definitive agreement by 31 March 2026.

The MoU includes customary provisions on exclusivity and confidentiality, which are binding on the parties. Apart from these provisions, the MoU does not constitute a binding commitment to complete the transaction. There can be no assurance that a definitive agreement will be entered into or that the transaction will be completed.

The Board of Directors of Simris considers the potential transaction to be aligned with the Company’s strategic priorities and, if completed, to have the potential to strengthen the Company’s financial position and strategic focus.

Further information will be communicated as the process progresses.

Contact Details:
Daniel Kubitza
Interim CEO of Simris Group AB
Email: daniel.kubitza@simris.com
Mobile: +33 6 71 04 21 52
www.simrisgroup.com

About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. 

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments
Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.